Day: October 19, 2021

Woven Science’s El Puente foundation is pleased to release for public comment its policy paper and corporate social responsibility initiative for psychedelic pharmaceutical companies to engage with indigenous peoples using psychedelic botanicals in traditional practice. This paper explores how public policymakers in collaboration with companies can offer indigenous communities influence over product development, consumer preferences, profit sharing, and public perception.

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) — Woven Science’s El Puente foundation is pleased to release for public comment its policy paper and corporate social responsibility initiative for psychedelic pharmaceutical companies to engage with indigenous peoples using psychedelic botanicals in traditional practice. This paper explores how public policymakers in collaboration with companies can offer indigenous communities influence over product development, consumer preferences, profit sharing, and public perception.

The public comment period will last the next 45 days. You can comment on the paper by filling in the intake form linked here or by emailing us directly at elpuente@woven.science. We will respond to your comments and integrate them into the final paper.

After interviewing leaders throughout both the psychedelics and pharmaceutical industries, we’ve identified four public policy solutions to explore:

• Bio-cultural conservation: legal action to protect against unsustainable harvesting of botanical psychedelic plants and preservation of indigenous cultural practices
• Appellations of Origin: indigenous intellectual property protection over the names and brands of psychedelics and their associated rituals
• Regulatory Sandboxes for entrepreneurship: giving special taxation and regulation exemptions for indigenous communities to develop products and provide services on the open market
• Financial sharing: mandates for how companies should share a portion of revenue with designated indigenous groups

Working with select partners for each, El Puente seeks to shape a more equitable, impactful, and responsible psychedelics sector. We invite you to join our series of community calls on these topics and join a working group to focus on the one that moves you most.

Stronger, together: thank you

Thank you to our many partners, peers, friends, and family for their input and feedback, with special thanks to Fundación Kene Rao for the quoted text, Frederick Research for the first draft of the paper, and Dr. Bronner’s, Riverstyx Foundation, ICEERS, Amazon Investor Coalition, McKenna Academy, and The Fountain for taking the time to speak with El Puente on ways to further these policy initiatives.

How can you support?

If you’re working in the nonprofit or for-profit sectors within the psychedelics, pharmaceutical, and/or biocultural conservation with indigenous peoples and you align with or wish to pursue any of these four initiatives, please visit our website for more information about how to partner with us and get involved.

About El Puente:  El Puente promotes access and benefit-sharing (ABS) with indigenous peoples and holds 10% of Woven’s equity. El Puente makes grants and investments in projects owned and operated by indigenous people and has a council of indigenous leaders serving as special advisors to the El Puente board with veto powers in project financing decisions, giving indigenous peoples seats at the table in the growing psychedelics sector.

About Woven Science: Woven Science builds, backs, and incubates best-in-class companies poised to drive profitable and scalable mental health outcomes across the entire psychedelic treatment arc from diagnosis to community and mental health sustainability. The Woven Science team and its advisors are seasoned professionals from the wellness, finance, biotech, neuroscience, and psychedelic arenas bringing extensive operational and strategic expertise to tackling the mental illness epidemic and recognizing that the path to sustained mental health requires multi-disciplinary and integrative models of care.

For media enquiries contact: hello@woven.science

This content was issued through the press release distribution service at Newswire.com.

Registration now open to the only global multidisciplinary conference featuring world-class speakers, cutting-edge research presentations, case study reviews and more specifically in the field of Atopic Dermatitis

“This year’s annual conference agenda is packed with symposia focused on emerging therapies, panel discussions led by industry leaders, industry sessions sponsored by global companies and the awarding of the new Totally ‘RAD’ Award,” said Dr. Jonathan I. Silverberg, MD, Ph.D., MPH, RAD Conference Chair. “The Annual Live RAD Conference offers great opportunities to hear about emerging therapies and industry ‘hot topics’ from the best in the field.”

New to this year’s Conference, the Totally “RAD” Award recognizes a healthcare provider in the dermatology field who has provided invaluable impact to patient care or research of AD. The recipient of the Totally “RAD” Award will receive a prize, complimentary registration to the December 2021 and 2022 conferences, as well as recognition on RAD’s website and social media. Nominations are due by November 19, 2021. Submit your nominee at http://revolutionizingad.com/award.

“I am excited to again be a part of the Annual Live RAD Conference and look forward to presenting on the current findings between COVID-19 and atopic dermatitis at Sunday’s Hot Topic session,” said Jacob P. Thyssen, MD, Ph.D., DmSci. “It is an honor to be part of an educational conference whose mission is to create a learning space where – through cutting-edge abstracts, case studies and oral presentations – we can all share in the latest advances and late-breaking research.”

RAD 2021 conference faculty include Jonathan I. Silverberg, MD, Ph.D., MPH, Conference Chair; Sabra Abbott, MD, Ph.D.; Katrina Abuabara, MD; Andrew Alexis, MD, Ph.D., MPH; Andrew Blauvelt, MD; Genery Booster, Ph.D.; Korey Capozza, MPH; Zelma Chiesa-Fuxench, MD, MSCE; Raj Chovatiya, MD, PhD; Mark Davis, MD; Aaron Drucker, MD; Anna Fishbein, MD; Phil Greenland, MD; Jon Hanifin, MD; Candrice Heath, MD; Peck Ong, MD; Amy S. Paller, MD, MS; Stephen Sheldon, DO; Eric Simpson, MD, MCR; Anne-Marie Singh, MD; Jacob P. Thyssen, MD, Ph.D., DmSci; Maria Wei, MD, Ph.D.; Prof. Stephan Weidinger, MD; Gil Yosipovitch, MD; and Phyllis Zee, MD, Ph.D.

More than 500 attendees are expected to register. To view the complete conference agenda, list of symposia leaders, and to register, visit RevolutionizingAD.com.

Saturday, December 11: 6:00 p.m. (EST) – Poster Viewing Opens

Sunday, December 12: 7:00 a.m. – 7:30 p.m. (EST)

Monday, December 13: 7:00 a.m. – 7:00 p.m. (EST)

Follow the RAD Conference on the following social media sites:

Linked in – linkedin.com/company/revolutionizingad/

Twitter – twitter.com/revatopicderm

Facebook – https://www.facebook.com/revolutionizingad

Press Contact: Patrice Melluso,  patrice@revolutionizingad.com

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Foundation for Dermatology Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

About the Foundation for Dermatology Education

The Foundation for Dermatology Education is devoted to educating dermatologists, allergists, primary care clinicians, nurse practitioners, physicians assistants, nurses, and other allied health professionals, and patients about atopic dermatitis.

Related Images

Image 1: RAD_2021_Logo

Revolutionizing Atopic Dermatitis 2021 Logo

This content was issued through the press release distribution service at Newswire.com.

Attachment

• RAD_2021_Logo

As WM has already developed and tested its functioning Global, Digital and multicurrency Digital currency for nearly a decade, it is aware of all the capacities of such instruments, and the responsibilities that go hand-in-hand with its creation and usage

On the other hand, Webtel.mobi (“WM”) has already created the required Global Digital Currency – and has already extensively tested it for nine years in worldwide operations. It therefore knows precisely what can and cannot be done with it, what it is capable of, and what changes it will bring about.

These are some of the capacities that the Global, Digital, Convertible, Transferrable, Acceptable, Redeemable Digital Medium of Exchange in, and of, all currencies – including “Standard TUVs”, Gold-backed “Secured TUVs” and Programmable “Smart TUVs” – within WM’s Global Clearing System with all its attendant Facilities – already bring about:

Tier 1 (standard) Capacities

• Instant Global Transfers and Payments with instant settlement
• 24/7/365 transactions from anywhere with any mobile phone
• Removal of intermediaries
• Rendering all transactions as Pure Peer-to-Peer (PP2P)
• Removal of transfer fees and costs
• Instant conversion to other currencies
• Redemption on demand of TUV’s Funds (“Stored Credit”) back to bank accounts
• Redemption on demand of TUV’s Funds (“Stored Credit”) via Kiosk withdrawals
• Multicurrency Accounts for TUV Owner and Merchants
• Control of FX Conversions for TUV Owners and Merchants
• Safety of digital money and utility of Cash
• Increased Anti Money Laundering capacity
• Increased Transaction and funds safety for owner
• Removal of Chargeback potential for Merchants
• Removal of Fraud for TUV Owner and Merchant
• Inclusion of Unbanked into the 21^st Century Digital Economy
• Reintroduction of gold-backed (“Gold Standard”) currency
• Introduction of Programmable currency

Those characteristics are, however, only the tip of the iceberg of what a Global, Digital, Convertible, Transferrable, Acceptable, Redeemable Digital Medium of Exchange in, and of, all currencies – with the Tier 1 capacities – provides.

An instrument with the Tier 1 capacities previously listed (and others which are not listed) fundamentally alters the structures and flows of the global payments, transfers, and transactions markets – but in a positive and progressive manner. Some of the alterations it brings about are as follow:

Tier 2 (intermediate) Capacities

• Provides a Global Currency Hedge Against Inflation or Currency Depreciation
  TUV Owners or Merchants can convert their funds (“Stored Credit”) to any other currency in their Multicurrency Accounts.

• Substitutes Payroll Companies and processes
  Companies can themselves program their own WM Accounts (very easily, rapidly, and simply) to instantly remit payroll payments (and all other payments) in bulk, worldwide, in multiple currencies, at any time, at zero cost.

• Substitutes Letter of Credit Companies and processes
  Sellers, Buyers and Shippers in shipping, logistics and other companies can directly between one-another program the terms of their agreements and their payment schedules / requirements into the “Smart TUVs”, in Revocable or Irrevocable terms, with or without a third-party curator of the transaction, in one or several currencies, with or without penalty clauses, etc. This removes the very high costs of intermediaries for a transaction and replaces them with zero-cost transactions (and ensures there are funds available for payment).

• Substitutes Escrow Account Companies and processes
  Parties to a transaction can either place a TUV into a third party’s WM account – or can program a “Smart TUV” between each other or with a third-party curator – all subject to the terms of the Escrow Agreement. Again, this can all be done instantly and at zero cost.

• Other Tier 2 (intermediate) capacities
  There are hundreds of Tier 2 capacities. All transactions that exist can be carried out using WM’s TUV Digital Currency for instant, secure and zero cost transactions. Other than the transactions it facilitates, WM’s TUV also provides all consumers and merchants with an all-in-one substitute for:
  • Card Payments or Card Payment Receipt
  • Payment Gateway Payments or Receipt
  • eWallet Payments or Receipt
  • Wire Transfer Payments or Receipt
  • Cash Payments or Receipt
  • All other Payment or Transfer types – worldwide
  • FX Conversions
  • Multicurrency Bank Accounts
  • Multiple other substitutes
    All of the above replaced with a single, global, uniform, secure, instant, and zero-cost alternative, 24/7/365

However, as useful as the Tier 1 and Tier 2 capacities are, they do not represent the limit of this instrument. The TUV – whether Standard, Secured or Smart – has multiple other uses at yet another level, as follows:

Tier 3 (advanced) Capacities

WM’s TUVs – combined with all other facilities within WM’s Global Clearing System – already provides instant, 24/7/365, zero cost, totally secure and intermediary-free (apart from the parties to the transactions) substitutes for the following (and multiple other) transactions, instruments, and markets:

• Derivative Currency Swaps
  Can be implemented at zero cost, instantly or over any period, with any variable terms programmed into the Smart TUV’s terms

• OTC Derivative Markets
  Can be implemented at zero cost, instantly or over any period, with any variable terms programmed into the Smart TUV’s terms

• Global FX Market
  Currency Swaps of TUVs can be implemented instantly, PP2P, 24/7/365, at zero cost, with conversion rates as agreed on between the two (or more) parties to the transaction.

• Global Clearing Systems
  The TUVs and WM’s Global Clearing System facilitates 24/7/365 instant and simultaneous payments, conversion, and settlement on a PvP and RTGS basis, with 100% liquidity, at zero cost

• Global Bond market
  Smart TUV’s can be programmed to replicate any form of Bond issue, with any terms or rates, over any period, with full security, security of funds, with or without curating parties – at zero cost.

• SWIFT / Other EFTs
  TUVs can be transferred worldwide, in 1/100^th of a second, 24/7/365, with full security and reporting, and at zero cost.

• Cash Replacement
  TUVs have all of the utility of cash, but with the safe storage, convenience, portability, and theft-prevention characteristics of digital money – as well as protection against counterfeiting and money laundering.

There are numerous and multiple other applications at this Tier level that TUVs can be used for.

Corporate and Social Responsibility
It is regrettable that the real capacities and advantages that have been brought about (past tense) by the creation of a Global, Digital, Convertible, Transferrable, Acceptable, Gold-Backer, Programmable, Redeemable Digital Medium of Exchange in, and of, all currencies are not discussed.

This is, however, understandable, as the entities that are in discussion stages probably wish to try to secure funding or prestige from being involved in their own forums.

However, this also results in not enough thought or discussion being applied to the ramifications of such an instrument and its capacities – and the requirement to build structures that will mitigate the consequences of these ramifications.

The major ramification is that of disintermediation of many thousands of intermediary companies worldwide. However, although this will substantially benefit consumers and merchants, it will impact negatively on thousands of companies and hundreds of thousands of jobs. Moreover, the intermediary companies and their personnel have done nothing wrong. They were necessary for the functioning of the legacy systems.

Consequently, WM has specifically modified its structure (one of the reasons for the long testing period and the rebuilding of platform 2) to ensure that these disintermediated intermediaries can play a role in the new system. This is either by transitioning to act as VSMPs within WM’s system – or by continuing their stand-alone status – to provide assistance, help and advisory services to clients, or by switching from using legacy systems to utilizing the new WM System within their existing businesses.

This ensures that WM’s “Evolution not Revolution” corporate philosophy is carried through into real-world application, and preservation of not just systemic stability, but also the stability of other companies and their personnel. These are considerations that all entities currently discussing these matters should view as priorities.

Resources:

Media Contact:
Nick Lambert: wm@thoburns.com

Video on the Capacities of the WM System:
https://youtu.be/XYBrCikUhn8

Research Reports on the Capacities of the WM System:
https://tinyurl.com/TUVresearch

Characteristics of WM’s TUV Digital Currency:
https://webtel.mobi/info/tuv-characteristics

WM’s “Secured TUV” Digital Currency:
https://webtel.mobi/info/my-secured-tuvs

WM’s “Smart TUV” Digital Currency:
https://webtel.mobi/info/my-smart-tuvs

WM’s urls:
https://webtel.mobi/pc (Tablets / Laptops / Desktops)
https://webtel.mobi (Smart Phones)
https://webtel.mobi/wap (Pre-Smart Mobile Phones)

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/07d81028-c5fc-401d-a109-a0799cb1d600. The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Ambulero Inc Receives Key FDA Recognition For Novel Gene Therapy To Treat Buerger’s Disease (Thromboangiitis Obliterans)

MIAMI, Oct. 19, 2021 (GLOBE NEWSWIRE) — Ambulero Inc., a biotechnology company (“Ambulero” or the “Company”) developing new cell and gene therapy treatments for patients suffering from severe vascular disease, today announced that the U.S. FDA’s Office For Orphan Products Development (OOPD) granted the company’s request for orphan drug status for its gene therapy candidate, AMB-301, to treat Buerger’s Disease (BD), also known as Thromboangiitis Obliterans (TAO).

AMB-301 is a first-in-class gene therapy vector encoding a cell adhesion molecule (E-selectin). Over a decade of research in animal models of vascular disease suggests that providing E-selectin to damaged blood vessels promotes therapeutic angiogenesis, robust tissue regeneration and improved limb function.

BD is a debilitating vascular disease that can lead to severe limb damage and amputation, often in relatively young patients. There are no effective treatments and existing therapies are largely ineffective. AMB-301 is a promising gene therapy candidate for enhancing blood vessel formation, restoring tissue integrity and eliminating the need for amputation as a treatment option.

The FDA’s orphan drug designation provides AMB-301 with seven (7) years of market exclusivity for the treatment of BD if approved. The FDA grants orphan designations to medical products showing promise to treat diseases that affect 200,000 or fewer Americans. The company is also eligible for certain tax credits and regulatory benefits with the FDA designation.

“Ambulero is honored to receive this important FDA recognition. Should clinical testing be successful, we believe our first-in-class gene therapy platform will provide new treatment options to patients suffering from BD and potentially other vascular diseases. The Orphan Drug Designation should also help expedite our BD clinical trial timeline,” said Robert L. Buchanan, Chief Executive Officer of Ambulero, Inc.

“It is very rewarding to offer a potential new therapy to so many patients facing amputation as the only treatment option for their disease,” said Carlton Anderson, Chief Operating Officer of Ambulero, Inc.

Ambulero’s Chief Regulatory Officer, Dr. Khemraj (Raj) Hirani added, “Receiving Orphan Drug Designation for AMB-301 is a significant step forward for BD patients and confirms the potential of our novel E-selectin based platform technology to accelerate clinical development.”

About Ambulero 
Ambulero is a privately-held biotechnology company advancing a new platform of cell and gene therapies to treat serious vascular diseases. The company is a recent spin-out of the University of Miami co-founded by Randy Berholtz, Robert L. Buchanan, Omaida C. Velazquez and Zhao-Jun Liu. Ambulero’s cell therapy program uses stromal cells engineered to express E-selectin to promote tissue repair. The company’s gene therapy program uses established approaches to administer E-selectin directly to injured vascular tissues. Ambulero is currently sourcing investors for a Series A round. See www.ambulero.com

Contact
Ambulero, Inc
Converge Miami
1951 NW 7^th Street, STE. 600
Miami, FL 33136
Dr. Carlton Anderson
Chief Operation Officer
Email: canderson@ambulero.com

Unified Top Companies Bring Unmatched Global Capabilities for Workplace Experience

BOSTON, Oct. 19, 2021 (GLOBE NEWSWIRE) — HqO, the end-to-end tenant experience platform for commercial real estate properties, today announces that it has acquired Office App, a leading European tenant and employee engagement platform. The new combined entity is valued at over half a billion dollars, making it one of the most significant proptech companies in the world. This valuation reflects the growing importance of workplace experience solutions in the commercial real estate market.

The acquisition brings together solutions for building owners and corporate workplaces, opening up a new market in the tenant experience space. It reinforces HqO’s leadership in the tenant experience category and positions it as the dominant global provider of workplace solutions for commercial real estate owners, property teams, and tenant companies. Furthermore, the Office App acquisition will help HqO increase its European footprint and accelerate product development to better support its customers, as Office App is currently active in 20 million square feet across over 100 offices in 24 countries.

“HqO is excited to welcome Office App to the HqO family,” said Chase Garbarino, Co-founder and CEO of HqO. “Providing tenant experience solutions that end at the suite door does not offer a truly connected experience for workers. Office App has done a tremendous job of building out a robust ecosystem of solutions tailored to the needs of European landlords and corporate occupiers. To that end, we are thrilled to be able to provide our customers a more complete offering with more consultation, higher user engagement rates, and more data.”

Currently, HqO services nearly 100 commercial real estate clients worldwide, including Columbia Property Trust, Nuveen Real Estate, Jamestown, Grosvenor, Hines, J.P. Morgan Asset Management, and Legal & General Investment Management. Office App services over 100 buildings worldwide with customers like Blackstone, Colliers, Dell, and Finastra.

HqO and Office App’s merger helps fulfill both company’s mission of transforming how employees engage with the workplace and its surrounding community. In today’s experience-based economy, tenant experience technology is a critical value driver for commercial real estate owners and operators looking to attract and retain tenants through highly personalized and frictionless experiences. By leveraging a toolset that can engage with customers and provide unique and meaningful interactions, properties can differentiate themselves against competition, keep up with the latest demands, and instill value in the workplace.

“The acquisition accelerates our mission to digitally transform workspaces, changing the landscape of the modern office and giving office workers everywhere access to the tools, services, and perks they need to live, work, and be happy,” says Thijs van der Burgt, Co-founder and CEO at Office App. “Together, we can better serve EMEA landlord and corporate clients, access our combined resources to execute on our short- and long-term strategies, and use our product and vision to support real estate on a global scale.”

The additional resources and product offerings made available as a result of the acquisition will improve HqO’s ability to meet the needs of their current and future customers. Both companies will also be able to leverage their shared knowledge and technology to accelerate product development and continue to provide best-in-class services and solutions to commercial landlords and property teams.

The acquisition follows HqO’s recent product announcements around flex space management and tenant satisfaction feedback to help landlords and property teams create complete customer-centric solutions for the workplace experience. The combined HqO-Office App entity will finalize in the following months and send a strong signal to the market about HqOs long-term commitment to becoming the best customer experience platform for commercial real estate clients. Both teams are confident that the whole of their two companies will be greater than the sum of their parts. For more information, visit https://www.hqo.com/.

About Office App

As Europe’s leading tenant and employee engagement platform, Office App provides landlords and corporates with a digital platform on which to create future-proof, sustainable, and people-focused office spaces. Founded in 2014 with the vision of creating a Happy Office Life for everyone, Office App is currently active in 20 million square feet divided over 100+ offices in 24 countries. For more information, visit https://getofficeapp.com/.

About HqO

The world’s leading commercial real estate firms count on HqO to help them deliver a state-of-the-art tenant experience within their properties. Active in over 150 million square feet in 8 countries, HqO is known for its tenant experience platform comprised of an award-winning tenant app, analytics suite, and partner marketplace. Our solutions put experiences and a sense of community directly into the tenants’ hands while helping property owners uncover insights and take intelligent action to differentiate their assets. For more information, visit www.hqo.com, and connect with us on LinkedIn, Twitter, and Instagram.

Primary Contact: Kristin Concannon
Phone: 833-225-5476
Email: kristin.concannon@hqo.co

The annual awards celebrate the beauty of the microscopic world through imaging

Contest Details
Prizes include an Olympus SZX7 stereo microscope with a DP28 digital camera for the global winner and an Olympus CX23 upright microscope for the regional winners in Asia, Europe and the Americas.

The international jury includes experts from both science and the arts, including Wendy Salmon, director of the Hooker Imaging Core Facility at the University of North Carolina (UNC) at Chapel Hill School of Medicine; Geoff Williams, manager of the Leduc BioImaging Facility at Brown University; Harini Sreenivasappa, microscopy facility manager of the Cell Imaging Center at Drexel University; Rachid Rezgui, research instrumentation scientist at New York University Abu Dhabi; Siân Culley, postdoctoral research associate at the MRC Laboratory for Molecular Cell Biology at UCL; Stefan Terjung, operational manager of the Advanced Light Microscopy Facility at EMBL Heidelberg; Wen-Biao Gan, director of the Institute of Neurological and Psychiatric Disorders at Shenzhen Bay Laboratory; and Anne Beghin, research assistant professor at MechanoBiology Institute, National University of Singapore.

All entries will be evaluated based on artistic and visual aspects, scientific impact and microscope proficiency.

About the Image of the Year (IOTY) Award
Olympus’ IOTY Award began in 2017 as the Image of the Year European Life Science Light Microscopy Award with the aim to celebrate both the artistic and scientific value of microscopy images. Today, the competition stays true to this mission by encouraging people around the world to look at scientific images in a new way, appreciate their beauty and share images with others.

More information about the Global Image of the Year Life Science Light Microscopy Award, including jury members’ biographies, last year’s winning images and the full terms and conditions, can be found at Olympus-LifeScience.com/IOTY.

For more information about Olympus Life Science, please visit Olympus-LifeScience.com.

About Olympus

Olympus is passionate about creating customer-driven solutions for the medical, life sciences and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent and treat disease; furthering scientific research; and ensuring public safety.

Olympus has manufactured microscopes since the company’s founding in 1919. Today, our Life Sciences business is dedicated to meeting and exceeding the evolving needs and expectations of life science professionals through a comprehensive range of clinical research, educational, and high-end research microscopes and microscope systems. For more information, visit Olympus-LifeScience.com.

Olympus and the Olympus logo are trademarks of Olympus Corporation or its subsidiaries.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7f5045d-ec30-4aef-8900-876aec195721

Media Contact:
Calla Kostelnik
610-973-2400
calla@klunkmillan.com

New report from RedThread Research and Degreed uncovers the actionable skills that build more diverse organizations, including assertiveness, grit, authenticity, and curiosity

PLEASANTON, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) — A new report, Creating a DEIB Culture: The Skills Every Employee Needs, by RedThread Research and sponsored by Degreed, has uncovered the actionable skills that build more diverse and inclusive organizations. Separated by seniority level, the list highlights practical ways for leaders, workers and senior managers to understand and build the skills needed to drive diversity, equity, inclusion and belonging (DEIB) at every level of their organization.

Diversity is on the boardroom agenda at many leading organizations. Skills are a necessary but often overlooked component of achieving diversity goals. According to the report, organizations that foster greater diversity are 81% more likely to have higher customer satisfaction and employees are 45% more likely to remain at their organization.

By employee group, the top skills for driving a DEIB culture are:

• Individual employee skills to act authentically: courage, authenticity, data literacy, pattern recognition, managing ambiguity and the ability to empower people.
• Manager skills to explore new ideas: curiosity, influence, negotiation and grit.
• Senior leader skills to push for change: mental flexibility, rapport building and assertiveness.

Additionally, two skills were found in all employees at all organizations with high DEIB — calculated risk-taking and nonverbal communications.

Susie Lee, SVP, Global Business Transformation & DEIB Executive Officer at Degreed said, “Traditional approaches to improving DEIB have fallen short at many companies. This new actionable skills data on inclusive organizations can be the catalyst that will finally drive change. And what’s really exciting is the actionability not just for HR, but across the entire business and for all job levels, because it’s only through making DEIB part of holistic business operations that true systemic change will occur.”

Janice Burns, Chief People Officer at Degreed said, “The business and societal benefits of having more inclusive organizations is now well-recognized but little has been done in terms of practical steps that leaders can take beyond hiring more diverse talent. I’m excited to see the impact this first-of-its-kind report from RedThread can have on driving change within DEIB efforts–across HR teams and the broader business community; it gives everyone a tangible way to build the foundations for an inclusive organization — one skill at a time.”

Both Susie and Janice will be speaking on this topic at Degreed LENS, held at the Intercontinental Hotel LA on November 11th. Reserve your event ticket here.

To read the full Creating a DEIB Culture: The Skills Every Employee Needs report, click here

Notes for editor:

Research Methodology

The Activating for DEIB report is a culmination of six months of qualitative and quantitative research beginning in March 2021. Starting with an exhaustive literature review of 60 articles, we then conducted extensive qualitative data collection, including two 80-minute roundtables which took place in April and May 2021, with 43 and 31 leaders, respectively, representing HR, DEIB, and learning in the first roundtable, and employees from all functions in the second roundtable. RedThread Research also conducted 60-minute interviews with 20 HR, DEIB, and learning leaders.

To collect the quantitative data, a 211 item survey was run from June to July 2021 covering organizational and individual demographics, organizational and individual performance, DEIB, skills importance and effectiveness, and other factors that could influence skills and DEIB. A total of 1,044 valid responses were collected.

For the skills portion of the survey, RedThread started with a list of close to 100 skills/competencies/behaviors that had been identified as critical during the qualitative portion of the research. Based on its own taxonomy, RedThread then grouped skills into “personal,” “interpersonal,” and “technical” and then minimized the list to 48 discrete skills that did not have any overlap and that satisfied four criteria:

• Granular
• What an employee does (vs. how a job is done)
• A learned ability
• Transferable within and across organizations

Respondents were asked within the survey to identify if a skill was important for themselves as individuals, their manager, and their most senior leader to create a culture of DEIB.

In the course of the analysis, RedThread created a DEIB Index, which included 6 questions designed to measure DEIB. These items include:
1. My org represents a diverse group of people (e.g., race, gender, age, disability, sexuality, education, religion, etc.).
2. People from all backgrounds and with a range of identities have equitable opportunities to advance at my org.
3. I feel respected by my colleagues.
4. I feel my unique background and identity are valued at my org.
5. I feel a sense of belonging at my org.
6. I feel included in the discussions and decisions that impact my job.

RedThread arrived at its conclusions by blending together insights from the quantitative and the qualitative research streams.

About Degreed
Degreed is the workforce upskilling platform for one in three Fortune 50 companies. We connect all your learning, talent development, and internal mobility opportunities to intelligence on the skills your business needs next. And we do it all in one simple, fluid, skill-building experience that’s powered by your people’s expertise and interests. So you can transform your workforce from within. Founded in 2012, Degreed is headquartered in Pleasanton, California, with additional offices in Salt Lake City, New York, London, Amsterdam, and Brisbane.

Learn more about Degreed: Website | YouTube | LinkedIn | Twitter

About RedThread Research
RedThread is a human capital research and advisory firm that listens to you and understands your business. We’re experts in talent management, learning, and diversity and inclusion and the technologies that support them. But more importantly, we’re truth-seekers and storytellers in a world where there’s a dearth of the former and much of the latter is sort of bunk. We use technology and collaboration to make connections between people, data, and ideas — even among seemingly unrelated concepts. We focus on providing high-quality, unbiased foresights that you can implement for a stronger business. For more information, please visit us at www.redthreadresearch.com. Follow RedThread on Twitter at @RedThreadRe.

Contact:
Sarah Danzl
Head of Global Communications, Degreed
sdanzl@degreed.com

Data to be presented at the 2021 ISIRV-WHO Virtual Conference

WALTHAM, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new in vitro data demonstrating retained neutralizing activity of its monoclonal antibody (mAb), ADG20, against a diverse panel of circulating SARS-CoV-2 variants, including the newly emerged Lambda and Mu variants. Notably, findings show that ADG20 demonstrated potent in vitro neutralizing activity against all SARS-CoV-2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under Emergency Use Authorization (EUA) or in late-stage development. These data will be presented during a poster session at the 2021 ISIRV-WHO Virtual Conference, which is being held October 19-21, 2021. In addition, Adagio will present an encore poster highlighting recently announced data from the company’s ongoing Phase 1 trial of ADG20 in healthy participants.

“These new variant data further underscore the potential of ADG20 to address the ongoing COVID-19 pandemic, as well as possible future outbreaks caused by other SARS-like viruses,” said Laura Walker, Ph.D., co-founder and chief scientific officer of Adagio. “We have intentionally designed this mAb to have both broad and potent neutralizing activity as well as a half-life that extends its potential window of protection, critical features that may set it apart from other therapies available under EUA or in development today. With global Phase 2/3 prevention and treatment trials ongoing, we look forward to continuing our evaluation of ADG20 to assess the meaningful role it could potentially play in the arsenal of COVID-19 treatment options. Given as a single, intramuscular injection in clinical trials, ADG20 has been designed to offer protection for up to a year in the prevention setting and is being explored as a treatment for high-risk patients and/or as a vaccine supplement, including for immunocompromised individuals.”

In addition to the Phase 1 healthy participant trial, Adagio is advancing two ongoing global Phase 2/3 trials with ADG20, a treatment trial (STAMP) and a prevention trial (EVADE). The company anticipates submitting an EUA application to the U.S. Food and Drug Administration for ADG20 in the first quarter of 2022.

Presentation Details
Poster Title: (130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19

Poster Title: (131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity in vivo against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA application, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and in Adagio’s future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:

Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com